ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
ResMed (RMD) Tops Q4 EPS by 7c
August 5, 2021 4:09 PM EDTResMed (NYSE: RMD) reported Q4 EPS of $1.35, $0.07 better than the analyst estimate of $1.28. Revenue for the quarter came in at $876.1 million versus the consensus estimate of $783.18 million.
Our fourth quarter and full-year fiscal year 2021 results continue to demonstrate the strength and resiliency of our business, said Mick Farrell, ResMeds CEO. During the quarter, we saw the ongoing recovery of core sleep apnea and COPD patient flow across... More
